长期小剂量罗红霉素联合氨溴索治疗支气管扩张症的疗效观察

Effect of Long-term Application of Roxithromycin at Low Dosage Combined with Ambroxol on Patients with Bronchiectasis

目的观察长期小剂量罗红霉素联合氨溴索在稳定期支气管扩张症中的临床疗效。方法选取2014年4月至2016年3月就诊于本院的84例支气管扩张患者为研究对象,根据随机数字表随机分为两组,每组42例。对照组患者给予氨溴索口服液,30mg/次,3次/日。观察组患者在对照组的基础上,加用罗红霉素每次150mg,每日1次。两组患者均接受6个月的治疗。分别测量治疗前后的痰量、肺功能及改良英国医学研究学会呼吸困难(modified British medical research council,mM RC)问卷,治疗期间观察药物的不良反应。结果两组患者治疗前的痰量、肺功能及呼吸困难评分相比,差异无统计学意义(P>0.05)。观察组患者治疗后的痰量较对照组明显减少,肺功能及呼吸困难评分均明显优于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生情况相比,差异无统计学意义(P>0.05)。结论小剂量罗红霉素联合氨溴索可显著改善支气管扩张症患者的咳痰、肺功能及呼吸困难等症状,临床效果显著,且不良反应少,可作为稳定期支气管扩张患者的长期治疗。

Objective To observe the effect of long - term application of roxithromycin at low dosage combined with ambroxol on patients with bronchiectasis. Methods 84 patients with bronchiectasis hospitalized during the period from April, 2014 to March, 2016 were selected and randomly divided into 2 groups： observation group and control group, 42 in each; ambroxol was administrated, 30 mg once and 3 times a day, to patients in both groups while roxithromy- cin, 150 mg once and once a day, was added to patients in observation group, the course for both groups lasted from 6 months; detection of sputum volume and lung function was made to all the patients in the 2 groups before and after treatment and the questionnaire of modified British medical research council （mMRC） was performed; the drug ad- verse effects were observed. Results There existed no statistical difference in sputum volume, lung function and the mMRC scores between the patients in the 2 groups before treatment （P 〉 0.05） while after treatment, the sputum vol- ume of the patients in observation group was much smaller than that of the patients in control group and the scores of lung function and mMRC in observation group were much superior to those in control group, the difference between the 2 groups was of statistical significance （P 〈 0.05） ; no statistical difference was found in the comparison of drug adverse effects between the 2 groups （P 〉0. 05）. Conclusions Roxithromycin combined with ambroxol is of obvious clinical effect but less drug adverse effects in improving the sputum volume, lung function and the symptoms of dyspnea in patients with bronchiectasis and it can be applied in the long - term treatment of patients with stable bronchiectasis.